Souders Financial Advisors Has $1.92 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Souders Financial Advisors cut its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 42.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 6,163 shares of the medical research company's stock after selling 4,633 shares during the quarter. Souders Financial Advisors' holdings in Amgen were worth $1,920,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of AMGN. Brighton Jones LLC increased its holdings in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Proficio Capital Partners LLC grew its holdings in Amgen by 35.0% in the 4th quarter. Proficio Capital Partners LLC now owns 1,806 shares of the medical research company's stock valued at $471,000 after buying an additional 468 shares in the last quarter. Madison Investment Advisors LLC acquired a new position in Amgen in the 4th quarter valued at $1,948,000. Blueshift Asset Management LLC acquired a new position in Amgen in the 4th quarter valued at $345,000. Finally, Whittier Trust Co. of Nevada Inc. grew its holdings in Amgen by 1.0% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 21,953 shares of the medical research company's stock valued at $5,722,000 after buying an additional 228 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president directly owned 8,162 shares in the company, valued at $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.76% of the stock is owned by company insiders.

Amgen Trading Up 0.4%

Amgen stock traded up $1.11 during trading hours on Monday, hitting $295.87. The stock had a trading volume of 2,024,698 shares, compared to its average volume of 2,839,651. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70. The stock has a market cap of $159.09 billion, a price-to-earnings ratio of 27.00, a P/E/G ratio of 2.66 and a beta of 0.49. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The business's 50 day simple moving average is $285.90 and its 200-day simple moving average is $289.56.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. The firm had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The business's quarterly revenue was up 9.4% on a year-over-year basis. During the same period last year, the company earned $3.96 earnings per share. On average, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on AMGN. Guggenheim began coverage on Amgen in a report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price objective on the stock. Piper Sandler reissued an "overweight" rating and set a $328.00 target price on shares of Amgen in a report on Friday, June 27th. Mizuho increased their target price on Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a report on Wednesday, May 7th. UBS Group increased their target price on Amgen from $315.00 to $326.00 and gave the stock a "neutral" rating in a report on Monday. Finally, Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Amgen currently has a consensus rating of "Hold" and an average price target of $308.32.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.